Abstract: Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

Abstract: A railway track defect detection system may include a mobile defect detection platform and a modal parameter analyzer. The platform may include an excitation mechanism (e.g., an excitation hammer or wheels that are in contact with a railway track) to apply multiple impact forces to the railway track while the platform travels along the railway track, and a laser Doppler vibrometer to capture, while the platform travels along the railway track, vibration data representing vibrations of the railway track caused by application of the multiple impact forces by the excitation mechanism. The modal parameter analyzer may be configured to detect, based on the vibration data captured by the laser Doppler vibrometer, a defect in the railway track. For example, changes in vibration amplitudes, mode shapes, damping ratios, or a natural frequency derived from the received vibration data may indicate the presence of a defect in the railway track.

Abstract: A method for fabricating a three-dimensional (3D) static random-access memory (SRAM) architecture using catalyst influenced chemical etching (CICE). Utilizing CICE, semiconductor fins can be etched with no etch taper, smooth sidewalls and no maximum height limitation. CICE enables stacking of as many nanosheet layers a desired and also enables a 3D stacked architecture for SRAM cells. Furthermore, CICE can be used to etch silicon waveguides thereby creating waveguides with smooth sidewalls to improve transmission efficiency and, for photon-based quantum circuits, to eliminate charge fluctuations that may affect photon indistinguishability.

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: Disclosed herein are technological solutions that are configured to limit sub-optimal visualization of the surgical field during robotic and manual laparoscopic surgery. Such technological solutions are configured to systematically assess cleanliness of an imaging element of a laparoscope (or other type of similar imaging apparatus) and take action for enabling or causing the imaging element to be cleaned. In preferred embodiments, assessment of the cleanliness of the imaging element provides information that can be used for enabling or causing cleaning of the imaging element to be performed in-vivo in either a manual, semi-autonomous or autonomous manner. In this manner such technological solutions advantageously enable the surgical field during surgery to be more efficiently and consistently maintained in an optimal condition.

Abstract: A tissue implantation device comprises a capsule; and a population of ultrasound-switchable fluorophores incorporated in the capsule. A method of imaging a tissue implantation device in a biological environment comprises disposing the tissue implantation device in a biological environment, the population of ultrasound-switchable fluorophores having a switching threshold in the biological environment; exposing the biological environment to an ultrasound beam to form an activation region within the biological environment; switching the ultrasound-switchable fluorophores in the activation region from an off state to an on state; exciting the ultrasound-switchable fluorophores in the activation region with a beam of electromagnetic radiation; and detecting light emitted by the ultrasound-switchable fluorophores.

Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.

Abstract: Autonomous wireless sensors in subsurface environments can be charged while present in the subsurface environment to allow the sensors to measure and wirelessly transmit measurements. The sensors rely upon a contrast agent to provide a power flow path to the sensors.

Abstract: The present disclosure provide for methods of using 6-thio-2?-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A11 allotype. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A31 and A33 allotypes. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

Abstract: A method can include receiving, at a computer system, characteristic values of a pregnancy of a subject. As an example, the characteristic values can include a numerical value for a live birth order of the pregnancy for the subject. The computer system can store a machine learning model that receives a first set of input features and provides a second set of one or more output values. In some embodiments, the first set of input features can correspond to the characteristic values of the pregnancy of the subject. The second set of one or more output values can include a probability of a Cesarean delivery. The characteristic values can be input into the machine learning model to obtain the probability of the Cesarean delivery being required for the subject during an attempt of a vaginal delivery. The Cesarean delivery can be performed based on the probability.

Abstract: Methods are provided for identifying tumor-specific antibodies and/or T-cell receptors by paired mRNA sequencing from individual immune cells in sentinel lymph nodes and comparison of these sequences with corresponding mass spectroscopy data from a subject having a cancer. Novel tumor-specific antibodies (e.g., NY-ESO-1-binding antibodies) are also provided.

Abstract: In one embodiment, a system for evacuating subdural hematomas includes an inlet configured to be placed in fluid communication with a subdural space, an irrigation reservoir in fluid communication with the inlet and configured to supply irrigation fluid to the inlet and the subdural space, an outlet separate from the inlet and also configured to be placed in fluid communication with the subdural space, and a pump in fluid communication with the outlet and configured to create negative pressure within the subdural space and evacuate fluid from the subdural space.

Abstract: A method for determining a radiotherapy treatment plan can include: receiving anatomical data for a patient; generating, via a neural network analyzing the anatomical data, a plurality of fitness values for a plurality of candidate beam orientations; determining a selected beam orientation based on the plurality of fitness values; performing a fluence map optimization (FMO) process on the selected beam orientation; and determining a dose distribution for the patient based on the FMO process.

Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).

Abstract: The disclosure provides for eRNA-targeted transcriptional reprogramming through targeted reduction of eRNAs for a clinically relevant gene, TNFSF10, resulting in a selective control of interferon-induced apoptosis. A method of inhibiting a TNFSF10 gene expression in a human cell is disclosed. The methods described herein comprise contacting the human cell with a single-stranded antisense compound consisting of the sequence selected from a set of SEQ ID NOs: disclosed herein, wherein the antisense compound targets an enhancer RNA (eRNA) transcribed from a genomic enhancer sequence or region. The eRNA is an TNFSF10 eRNA sequence comprising the nucleic acid sequence selected from the SEQ ID NOs disclosed herein which inhibits expression of the TNFSF10 gene in the human cell.

Abstract: Methods, apparatuses, systems, and implementations for inductive heating of a foreign metallic implant are disclosed. A foreign metallic implant may be heated via AMF pulses to ensure that the surface of the foreign metallic implant heats in a uniform manner. As the surface temperature of the foreign metallic implant rises, acoustic signatures may be detected by acoustic sensors that may indicate that tissue may be heating to an undesirable level approaching a boiling point. Once these acoustic signatures are detected, the AMF pulses may be shut off for a time period to allow the surface temperature of the implant to cool before applying additional AMF pulses. In this manner, the surface temperature of a foreign metallic implant may be uniformly heated to a temperature adequate to treat bacterial biofilm buildup on the surface of the foreign metallic implant without damaging surrounding tissue.